Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Virology

• Publication date

  2004-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.78.20.11198-11207.2004PMID 15452239PMCID PMC521851
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design.

  2004cited by this paper
• Determinants of the Host Range Restriction of Replication of Bovine Parainfluenza Virus Type 3 in Rhesus Monkeys Are Polygenic

  2003cited by this paper
• Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.

  2003cited by this paper
• Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3′ Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity

  2003cited by this paper
• Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection.

  2003cited by this paper
• Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates.

  2003influential reference
• A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants

  2003cited by this paper
• Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.

  2003cited by this paper
• Palivizumab in the prevention of respiratory syncytial virus disease

  2002cited by this paper
• Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone

  2002cited by this paper
• Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.

  2002cited by this paper
• Respiratory syncytial virus: reverse genetics and vaccine strategies.

  2002cited by this paper
• Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

  2001cited by this paper
• R ESPIRATORY S YNCYTIAL V IRUS AND P ARAINFLUENZA V IRUS

  2001cited by this paper
• Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.

  2001cited by this paper
• Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.

  2001cited by this paper
• Respiratory syncytial virus and parainfluenza virus.

  2001cited by this paper
• Expression of the Surface Glycoproteins of Human Parainfluenza Virus Type 3 by Bovine Parainfluenza Virus Type 3, a Novel Attenuated Virus Vaccine Vector

  2000cited by this paper
• African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.

  2000cited by this paper
• Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

  2000cited by this paper
• A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.

  2000cited by this paper
• Respiratory syncytial virus: A continuing culprit and conundrum.

  1999cited by this paper
• Respiratory Syncytial Virus Vaccines

  1998cited by this paper
• Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.

  1998cited by this paper
• Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

  1997cited by this paper
• Animal models of respiratory syncytial virus infection.

  1997cited by this paper
• Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.

  1997cited by this paper
• Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.

  1996cited by this paper
• Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

  1996cited by this paper
• Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

  1996cited by this paper
• A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

  1995cited by this paper
• Respiratory syncytial virus and influenza A infections in the hospitalized elderly.

  1995cited by this paper
• A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.

  1993cited by this paper
• Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.

  1992cited by this paper
• Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived

  1991cited by this paper
• Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.

  1990cited by this paper
• Immunogenicity and pathogenicity of temperature‐sensitive modified respiratory syncytial virus in adult volunteers

  1988cited by this paper
• Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

  1988cited by this paper
• Candidates

  1982cited by this paper
• Attenuated Respiratory Syncytial Virus Vaccines in Asthmatic Children

  1974cited by this paper
• Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children.

  1973cited by this paper
• Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

  1969cited by this paper

• Novel BPI3Vc-vectored surface displayed fusion and hemagglutinin-neuraminidase antigens elicit broadly neutralizing antibodies in cattle.

  2026cites this paper
• Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3

  2025cites this paper
• [Acute respiratory viral infections in monkeys].

  2025cites this paper
• The Development of Animal Models for Respiratory Syncytial Virus (RSV) Infection and Enhanced RSV Disease

  2024cites this paper
• Preclinical animal models to evaluate therapeutic antiviral antibodies.

  2024cites this paper
• Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview

  2024cites this paper
• Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

  2022cites this paper
• Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

  2022cites this paper
• From animal studies into clinical trials: the relevance of animal models to develop vaccines and therapies to reduce disease severity and prevent hRSV infection

  2022cites this paper
• One mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

  2021cites this paper
• Engineering of Live Chimeric Vaccines against Human Metapneumovirus

  2020cites this paper
• Establishment of a lethal aged mouse model of human respiratory syncytial virus infection

  2019cites this paper
• Current Animal Models for Understanding the Pathology Caused by the Respiratory Syncytial Virus

  2019cites this paper
• Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate

  2017cites this paper
• Respiratory syncytial virus: an overview of infection biology and vaccination strategies

  2017cites this paper
• Animal models of respiratory syncytial virus infection

  2017cites this paper
• Respiratory syncytial virus elicits enriched CD8+ T lymphocyte responses in lung compared with blood in African green monkeys

  2017cites this paper
• Experimental animal model for analyzing immunobiological responses following vaccination with formalin‐inactivated respiratory syncytial virus

  2016cites this paper
• Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus

  2016cites this paper
• Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses

  2016cites this paper
• Virus para-influenza humain/bovin recombinant 3 (b/hpiv3) exprimant une protéine f chimérique du rsv/bpiv3 et ses utilisations

  2016cites this paper
• RNA-based viral vectors

  2015cites this paper
• Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques.

  2015cites this paper
• A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.

  2015cites this paper
• Cross-immunity between strains explains the dynamical pattern of paramyxoviruses

  2015cites this paper
• Inducible nitric oxide synthase (iNOS) regulatory region variation in non-human primates.

  2015cites this paper
• A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective TH1-Type Humoral and Cellular Immunity In Rodent Models

  2015cites this paper
• Respiratory Virus Vaccines

  2015cites this paper
• Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate

  2015cites this paper
• Enzyme-Linked Immunospot Assay for Detection of Human Respiratory Syncytial Virus F Protein-Specific Gamma Interferon-Producing T Cells

  2014cites this paper
• Novel Vaccine Regimen Elicits Strong Airway Immune Responses and Control of Respiratory Syncytial Virus in Nonhuman Primates

  2014cites this paper
• PrimatesSyncytial Virus in Nonhuman Airway Immune Responses and Control of Novel Vaccine Regimen Elicits Strong

  2014cites this paper
• Vero/BC-F: an efficient packaging cell line stably expressing F protein to generate single round-infectious human parainfluenza virus type 2 vector

  2014cites this paper
• An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory 1

  2014cites this paper
• Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age

  2013cites this paper
• Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.

  2013cites this paper
• Respiratory Syncytial Virus: Current Progress in Vaccine Development

  2013cites this paper
• Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.

  2013cites this paper
• Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.

  2013cites this paper
• Recent developments with live‐attenuated recombinant paramyxovirus vaccines

  2013cites this paper
• Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.

  2013cites this paper
• The N500 Glycan of the Respiratory Syncytial Virus F Protein is Required for Fusion, but Not for Stabilization or Triggering of the Protein

  2013cites this paper
• Development and verification of real-time PCR assay for identification of viral agents causing acute respiratory infections in human beings

  2013cites this paper
• Mechanisms of resistance for human respiratory syncytial virus isolates against anti-fusion agents in tissue culture

  2012cites this paper
• Treatment of Respiratory Syncytial Virus Infection : Past , Present and Future

  2012cites this paper
• Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350

  2012cites this paper
• Targeting RSV with vaccines and small molecule drugs.

  2012cites this paper
• The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development

  2012cites this paper
• Sendai virus-based RSV vaccine protects African green monkeys from RSV infection.

  2012cites this paper
• Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children

  2012cites this paper
• Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein

  2012cites this paper
• Neonatal Calf Infection with Respiratory Syncytial Virus: Drawing Parallels to the Disease in Human Infants

  2012cites this paper
• Respiratory Syncytial Virus: Rodent Models and Vaccine Development

  2012cites this paper
• A review of palivizumab and emerging therapies for respiratory syncytial virus

  2011cites this paper
• Human Metapneumovirus: Lessons Learned over the First Decade

  2011cites this paper
• Respiratory syncytial virus vaccine development

  2011cites this paper
• Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

  2011cites this paper
• Progress in the development of human parainfluenza virus vaccines

  2011cites this paper
• Progress in Respiratory Virus Vaccine Development

  2011cites this paper
• Live Attenuated Vaccines for Respiratory Syncytial Virus

  2011cites this paper
• Honey as an antiviral agent against respiratory syncytial virus

  2011cites this paper
• Treatment of Respiratory Syncytial Virus Infection: Past, Present and Future

  2011cites this paper
• Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

  2010cites this paper
• AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats

  2010cites this paper
• Mucosal vaccines: novel advances in technology and delivery

  2009cites this paper
• Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients

  2009cites this paper
• PHASE-I STUDY MEDI-534, OF A LIVE, ATTENUATED INTRANASAL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS AND PARAINFLUENZA-3 VIRUS IN SEROPOSITIVE CHILDREN

  2009cites this paper
• Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus

  2009cites this paper
• Vaccines: the Fourth Century

  2009cites this paper
• Challenges in developing a pediatric RSV vaccine

  2009cites this paper
• Infected Patients Syncytial Virus Derived from B Cells of Treatment and Prophylaxis of Respiratory Potent High-Affinity Antibodies for

  2009cites this paper
• Respiratory syncytial virus vaccine development.

  2009cites this paper
• Rekombinante bovin-humane Parainfluenzaviren Typ 3 als Impfvektoren gegen nicht-virale Antigene

  2008cites this paper
• Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.

  2008cites this paper
• New developments in vaccines against respiratory viruses.

  2008cites this paper
• Current status of vaccines for parainfluenza virus infections.

  2008cites this paper
• The Fusion Protein of Respiratory Syncytial Virus Triggers p53-Dependent Apoptosis

  2008cites this paper
• Human and bovine respiratory syncytial virus vaccine research and development.

  2008cites this paper
• Nouvelles stratégies de la vaccination

  2008cites this paper
• [New vaccination strategies].

  2008cites this paper
• Understanding the mechanisms of viral induced asthma: New therapeutic directions

  2008cites this paper
• Community-acquired pneumonia: paving the way towards new vaccination concepts

  2007cites this paper
• Immunization strategies for the prevention of pneumovirus infections

  2007cites this paper
• Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.

  2007cites this paper
• Immunopathology of RSV infection: prospects for developing vaccines without this complication

  2007cites this paper
• Experimental infection of macaques with human metapneumovirus induces transient protective immunity.

  2007cites this paper
• Virus Triggers P53-dependent Apoptosis the Fusion Protein of Respiratory Syncytial

  2007cites this paper
• Past, present and future of RSV and PIV vaccines and anti-RSV antibodies for the protection of humans against RSV

  2007cites this paper
• Progress in respiratory virus vaccine development.

  2007cites this paper
• A serum-free Vero production platform for a chimeric virus vaccine candidate

  2006cites this paper
• Vaccines against Human Respiratory Syncytial Virus

  2006cites this paper
• Respiratory syncytial virus: immunopathology and control

  2006cites this paper
• Respiratory Syncytial Virus Vaccine

  2006cites this paper
• Modification of the Trypsin-Dependent Cleavage Activation Site of the Human Metapneumovirus Fusion Protein To Be Trypsin Independent Does Not Increase Replication or Spread in Rodents or Nonhuman Primates

  2006cites this paper
• A review of vaccine research and development: Human acute respiratory infections

  2005cites this paper
• Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates

  2005cites this paper
• Carriers for the delivery of a vaccine against respiratory syncytial virus

  2005influential citation
• Respiratory Syncytial Virus Infections: Old Challenges and New Opportunities

  2005cites this paper
• An S101P Substitution in the Putative Cleavage Motif of the Human Metapneumovirus Fusion Protein Is a Major Determinant for Trypsin-Independent Growth in Vero Cells and Does Not Alter Tissue Tropism in Hamsters

  2005cites this paper
• Recombinant Sendai Virus as a Novel Vaccine Candidate for Respiratory Syncytial Virus

  2005cites this paper